ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma m
ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.